Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

Abstract Introduction Cisplatin-based neoadjuvant chemotherapy (NAC) followed by surgery is the standard treatment for patients with non-metastatic muscle invasive bladder cancer (MIBC). Unfortunately, many patients are not candidates to receive cisplatin due to renal impairment. Additionally, no pr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, Aurélien Carnot, Thierry Gil, Vinciane Casert, Vincent Vanhaudenarde, Brieuc Sautois, Lionel Staudacher, Jan Van den Brande, Stephane Culine, Emmanuel Seront, Marco Gizzi, Simone Albisinni, Thibault Tricard, Jean Christophe Fantoni, Marianne Paesmans, Rafael Caparica, Thierry Roumeguere, Ahmad Awada
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
Avelumab
Bladder cancer
Checkpoint inhibitor
Immunotherapy
Neoadjuvant
PD-1 blockade
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/ed1c1c1bbabd472db077410bfa15798e
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/ed1c1c1bbabd472db077410bfa15798e

Documents similaires